Mark Cookson received his PhD in cell biology in 1995 from the University of Salford, United Kingdom (UK). His began his career with the National Institutes of Health in 2002 as a senior research fellow in the Laboratory of Neurogenetics (LNG). From 2004 to 2009, Dr. Cookson served as a tenure-track investigator, until he received tenure in 2009, and became a senior investigator and chief of the Cell Biology and Gene Expression Section (CBGES) in LNG. Starting in 2020, Dr. Cookson served as the acting chief of LNG, and he was subsequently promoted to chief of LNG in 2022. Dr Cookson’s research interests are focused on the molecular effects of mutations associated with age-related neurodegenerative diseases, particularly Parkinson’s disease.